NGNE
Price
$17.77
Change
+$0.35 (+2.01%)
Updated
Sep 26, 01:15 PM (EDT)
Capitalization
248.4M
VRDN
Price
$19.55
Change
+$0.47 (+2.46%)
Updated
Sep 26, 01:33 PM (EDT)
Capitalization
1.56B
53 days until earnings call
Interact to see
Advertisement

NGNE vs VRDN

Header iconNGNE vs VRDN Comparison
Open Charts NGNE vs VRDNBanner chart's image
Neurogene
Price$17.77
Change+$0.35 (+2.01%)
Volume$100
Capitalization248.4M
Viridian Therapeutics
Price$19.55
Change+$0.47 (+2.46%)
Volume$212
Capitalization1.56B
NGNE vs VRDN Comparison Chart in %
Loading...
NGNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NGNE vs. VRDN commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NGNE is a StrongBuy and VRDN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (NGNE: $17.41 vs. VRDN: $19.08)
Brand notoriety: NGNE and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NGNE: 94% vs. VRDN: 70%
Market capitalization -- NGNE: $248.4M vs. VRDN: $1.56B
NGNE [@Biotechnology] is valued at $248.4M. VRDN’s [@Biotechnology] market capitalization is $1.56B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NGNE’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • NGNE’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, VRDN is a better buy in the long-term than NGNE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NGNE’s TA Score shows that 5 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • NGNE’s TA Score: 5 bullish, 5 bearish.
  • VRDN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both NGNE and VRDN are a good buy in the short-term.

Price Growth

NGNE (@Biotechnology) experienced а -6.83% price change this week, while VRDN (@Biotechnology) price change was -2.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.01%. For the same industry, the average monthly price growth was +9.06%, and the average quarterly price growth was +48.80%.

Reported Earning Dates

VRDN is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($1.56B) has a higher market cap than NGNE($248M). VRDN YTD gains are higher at: -0.469 vs. NGNE (-23.863). NGNE has higher annual earnings (EBITDA): -81.25M vs. VRDN (-340.62M). VRDN has more cash in the bank: 563M vs. NGNE (275M). NGNE has less debt than VRDN: NGNE (12.9M) vs VRDN (21.3M). VRDN has higher revenues than NGNE: VRDN (305K) vs NGNE (0).
NGNEVRDNNGNE / VRDN
Capitalization248M1.56B16%
EBITDA-81.25M-340.62M24%
Gain YTD-23.863-0.4695,083%
P/E RatioN/AN/A-
Revenue0305K-
Total Cash275M563M49%
Total Debt12.9M21.3M61%
FUNDAMENTALS RATINGS
NGNE vs VRDN: Fundamental Ratings
NGNE
VRDN
OUTLOOK RATING
1..100
7572
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
94
Overvalued
PROFIT vs RISK RATING
1..100
10083
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
6344
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NGNE's Valuation (63) in the null industry is in the same range as VRDN (94) in the Biotechnology industry. This means that NGNE’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as NGNE (100) in the null industry. This means that VRDN’s stock grew similarly to NGNE’s over the last 12 months.

NGNE's SMR Rating (97) in the null industry is in the same range as VRDN (99) in the Biotechnology industry. This means that NGNE’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Price Growth Rating (44) in the Biotechnology industry is in the same range as NGNE (63) in the null industry. This means that VRDN’s stock grew similarly to NGNE’s over the last 12 months.

VRDN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NGNE (100) in the null industry. This means that VRDN’s stock grew similarly to NGNE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NGNEVRDN
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
85%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 1 day ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
NGNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
XFABF8.380.04
+0.48%
X-FAB SILICON FOUNDRIES SE
LUCN5.40N/A
N/A
Lucent, Inc.
FKKFY15.00N/A
N/A
Fukuoka Financial Group, Inc.
HLEO0.65N/A
N/A
Helio Corporation
DNBBY26.48-0.31
-1.16%
DNB ASA

NGNE and

Correlation & Price change

A.I.dvisor indicates that over the last year, NGNE has been loosely correlated with BRNS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NGNE jumps, then BRNS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGNE
1D Price
Change %
NGNE100%
+0.90%
BRNS - NGNE
51%
Loosely correlated
+2.63%
RNAZ - NGNE
48%
Loosely correlated
-4.71%
ZNTL - NGNE
47%
Loosely correlated
-1.97%
IRON - NGNE
45%
Loosely correlated
+0.18%
VRDN - NGNE
43%
Loosely correlated
-2.15%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with SYRE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
-2.15%
SYRE - VRDN
58%
Loosely correlated
-8.18%
CRNX - VRDN
56%
Loosely correlated
+2.02%
NUVL - VRDN
55%
Loosely correlated
-2.54%
AURA - VRDN
53%
Loosely correlated
-4.70%
BEAM - VRDN
52%
Loosely correlated
-2.12%
More